**Dear editor**

In a recently published article[@b1-idr-11-427] moxalactam has been claimed to be very effective on extended-spectrum β-lactamase-producing *Escherichia coli* and *Klebsiella pneumoniae*, concluding "MOX demonstrated excellent bactericidal effect, which is worthy of further exploration to serve as an alternative therapeutic agent against ESBL-producing Enterobacteriaceae". Similar claims have also been made earlier.[@b2-idr-11-427] Out of interest we examined antimicrobial sensitivity data with reference to sensitivity to moxalactam, carbapenem resistant, and extended-spectrum β-lactamase (EBSL) and metallo-β-lactamase (MBL) production, among clinically important bacteria from the last 6 years (2011--2017), available from the Division of Epidemiology at Indian Veterinary Research Institute, Izatnagar.

The analysis ([Figure 1](#f1-idr-11-427){ref-type="fig"}) revealed that conclusions drawn earlier[@b1-idr-11-427],[@b2-idr-11-427] on the basis of a study on a few strains may not be valid. My analysis revealed that of the 3,242 bacteria tested in our laboratory, using Clinical and Laboratory Standards Institute[@b3-idr-11-427] guidelines, 50.6% were identified as ESBL producers. Observations further revealed that moxalactam was certainly a more effective antibiotic on clinically important bacteria than most of the extended spectrum β-lactam antibiotics but no significant difference was detected between ESBL and non-ESBL producer bacteria with respect to their sensitivity to carbapenem (meropenem, imipenem and ertapenem), moxalactam and aztreonam. However, non-ESBL producing bacteria were more often positive for MBL production (*p* \<0.001) than ESBL producing bacteria. Therefore, it may be suggested that observations on a few strains should not be used to draw a generalized statement the moxalactam is more effective on ESBL producer strains. It may give false message for misuse or undue preferences for moxalactum use.
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**Dear editor**

We thank Dr Singh for his comments on our recently published article.[@b4-idr-11-427] We are in favor of his view, "observations on a few strains should not be used to draw a generalized statement". As we mentioned, moxalactam (MOX) is worthy of further exploration to serve as an alternative therapeutic agent against extended-spectrum β-lactamase (EBSL)-producing Enterobacteriaceae. Our data showed that MOX was more effective than cefotaxime and cefoperazone/sulbactam against ESBL-producing Enterobacteriaceae. However, it was not used for the treatment of metallo-β-lactamase (MBL) producers. Further explorations are still urgently needed so as to demonstrate stable efficacy of MOX against ESBL producers and decrease the usage of carbapenems. Moreover, our recent epidemiology antimicrobial surveillance isolated from bloodstream infections in China found that the resistance of ESBL producers to MOX was close to that of carbapenems (data not shown). In addition, we are confused regarding the data on Dr Singh's [Figure 1](#f1-idr-11-427){ref-type="fig"}. It was strange that the resistance rates to aztreonam in both ESBL- and non-ESBL-producing isolates were nearly identical, and ESBL producers were 48.95% resistant to aztreonam.

Finally, we are grateful for your attention to our published results.

**Disclosure**

The authors report no conflicts of interest in this communication.
